Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Experience in the management of severe COVID-19 patients in an intensive care unit

Sosa-García et al., Cir Cir. 2020, 88:5, 569-575, doi:10.24875/CIRU.20000675
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -11% Improvement Relative Risk HCQ for COVID-19  Sosa-García et al.  ICU PATIENTS Is very late treatment with HCQ beneficial for COVID-19? Retrospective 56 patients in Mexico Study underpowered to detect differences c19hcq.org Sosa-García et al., Cir Cir. 2020, 569.., Jun 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 418 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
5,000+ studies for 104 treatments. c19hcq.org
Small retrospective study of 56 ICU patients in Mexico showing HCQ RR 1.1, p = 1.0.
This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline; substantial unadjusted confounding by indication likely.
risk of death, 10.5% higher, RR 1.11, p = 1.00, treatment 7 of 38 (18.4%), control 3 of 18 (16.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sosa-García et al., 29 Jun 2020, retrospective, Mexico, peer-reviewed, baseline oxygen required 100.0%, 6 authors, average treatment delay 9.0 days.
This PaperHCQAll
Experiencia en el manejo de pacientes graves con COVID-19 en una unidad de terapia intensiva
J Ojino Sosa-García, Alan O Gutiérrez-Villaseñor, Alondra García-Briones, Juan P Romero-González, Eva Juárez-Hernández, Octavio González-Chon
Cirugía y Cirujanos, doi:10.24875/ciru.20000675
Objetivo: Describir las características clínicas y el manejo de pacientes graves con COVID-19. Método: Estudio observacional, descriptivo, longitudinal y restrospectivo. Resultados: Ingresaron 56 pacientes, el 80.3% (n = 45) de sexo masculino, con un promedio de edad de 58 [46-67] años. Las principales condiciones de comorbilidad fueron obesidad, hipertensión y diabetes. El tiempo de inicio de los síntomas al ingreso fue de 9 [7-14] días, siendo los más frecuentes disnea, fiebre y tos seca. Los datos de laboratorio fueron linfopenia y elevación de deshidrogenasa láctica, fibrinógeno, dímero D, ferritina y proteína C reactiva. El 100% de los pacientes requirieron ventilación mecánica, con una mediana de tiempo de ventilación de 12 [6-17] días, y el 66% (n = 37) requirieron posición en prono. El tratamiento farmacólogico fue a base de azitromicina, hidroxicloroquina, tocilizumab y esteroides, principalmente. Las complicaciones más frecuentes fueron lesión renal aguda, enfermedad tromboembólica venosa e infarto agudo al miocardio. La tasa de mortalidad fue del 17.8% (n = 10). Conclusión: Los pacientes graves en nuestro hospital fueron en su mayoría personas de la tercera edad y con obesidad, siendo las variables de mayor puntaje SOFA y lesión renal aguda las asociadas con mayor mortalidad.
References
Arentz, Yim, Klaff, Lokhandwala, Riedo et al., Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State, JAMA
Bhatraju, Ghassemieh, Nichols, Kim, Jerome et al., Covid-19 in critically ill patients in the Seattle Region -case series, N Engl J Med
Cao, Wang, Wen, Liu, Wang et al., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate use of remdesivir for patients with severe COVID-19, N Engl J Med
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Reding-Bernal, Sánchez-Pedraza, Moreno-Macías, Sobrino-Cossio, Barrera et al., Heritability and genetic correlation between GERD symptoms severity, metabolic syndrome, and inflammation markers in families living in Mexico City, PLoS One
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA
Who, Pneumonia of unknown cause -China
Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
{ 'indexed': {'date-parts': [[2023, 5, 11]], 'date-time': '2023-05-11T22:13:05Z', 'timestamp': 1683843185568}, 'reference-count': 0, 'publisher': 'Publicidad Permanyer, SLU', 'issue': '5', 'content-domain': {'domain': ['www.cirugiaycirujanos.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 10, 6]]}, 'DOI': '10.24875/ciru.20000675', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 17]], 'date-time': '2020-09-17T17:31:54Z', 'timestamp': 1600363914000}, 'update-policy': 'http://dx.doi.org/10.24875/ciru.policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Experiencia en el manejo de pacientes graves con COVID-19 en una unidad de terapia intensiva', 'prefix': '10.24875', 'volume': '88', 'author': [ {'given': 'J. Ojino', 'family': 'Sosa-García', 'sequence': 'first', 'affiliation': []}, { 'given': 'Alan O.', 'family': 'Gutiérrez-Villaseñor', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alondra', 'family': 'García-Briones', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juan P.', 'family': 'Romero-González', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eva', 'family': 'Juárez-Hernández', 'sequence': 'additional', 'affiliation': []}, {'given': 'Octavio', 'family': 'González-Chon', 'sequence': 'additional', 'affiliation': []}], 'member': '10499', 'published-online': {'date-parts': [[2020, 10, 6]]}, 'container-title': 'Cirugía y Cirujanos', 'original-title': [], 'language': 'es', 'link': [ { 'URL': 'https://www.cirugiaycirujanos.com/frame_esp.php?id=358', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 5, 11]], 'date-time': '2023-05-11T21:52:41Z', 'timestamp': 1683841961000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.cirugiaycirujanos.com/frame_esp.php?id=358'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10, 6]]}, 'references-count': 0, 'journal-issue': { 'issue': '5', 'published-online': {'date-parts': [[2020, 10, 6]]}, 'published-print': {'date-parts': [[2020, 10, 6]]}}, 'URL': 'http://dx.doi.org/10.24875/CIRU.20000675', 'relation': {}, 'ISSN': ['0009-7411'], 'subject': ['Surgery'], 'container-title-short': 'CIRU', 'published': {'date-parts': [[2020, 10, 6]]}, 'assertion': [ { 'value': 'Artículo original / Original article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '2020-06-19', 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-06-29', 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2020-10-06', 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit